Islet-amyloid deposits, which are a common feature of Type II diabetes mellitus, are derived from the polymerization of a putative hormone identified as IAPP. IAPP is synthesized by normal islet beta cells and probably is cosecreted with insulin. Although the physiologic function of IAPP and its role in the pathogenesis of Type II diabetes mellitus are just beginning to be unraveled, IAPP may play an important part in the development of this most common form of diabetes mellitus by opposing the action of insulin in peripheral tissues. The polymerization of IAPP to form extracellular islet-amyloid deposits may further contribute to the development of Type II diabetes mellitus by destroying islet cells and by disrupting the passage of glucose and hormones to and from them. Substantial evidence indicates that the propensity of IAPP to polymerize and form extracellular amyloid deposits in only certain species (e.g., humans, cats, and raccoons) is directly associated with an intrinsically amyloidogenic part of the molecule--i.e., positions 20 through 29 of IAPP. The inherent amyloidogenicity of IAPP in these species may be further facilitated by increased beta-cell production of IAPP, leading to a high local concentration that predisposes to polymerization. The latter possibility is supported by studies demonstrating that IAPP production by islet beta cells is increased in normoglycemic cats with impaired glucose tolerance. Although increased production of IAPP may initially cause insulin resistance, prolonged overproduction of IAPP may ultimately impair insulin secretion by leading to the progressive deposition of insoluble islet amyloid, a finding apparent in most subjects with overt diabetes. If, as these studies suggest, increased IAPP production is linked to the development of Type II diabetes mellitus, further studies must address the genetic and nongenetic factors that influence this important biologic change in humans and some animal species.
Source Information
Department of Veterinary Pathobiology, College of Veterinary Medicine, University of Minnesota, St. Paul 55108.
This article has been cited by other articles:
DeFronzo, R. A.
(2009). From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus. Diabetes
58: 773-795
[Full Text]
Bonner-Weir, S., O'Brien, T. D.
(2008). Islets in Type 2 Diabetes: In Honor of Dr. Robert C. Turner. Diabetes
57: 2899-2904
[Full Text]
Herczenik, E., Gebbink, M. F. B. G.
(2008). Molecular and cellular aspects of protein misfolding and disease. FASEB J.
22: 2115-2133
[Abstract][Full Text]
Hamir, A. N., Kunkle, R. A., Miller, J. M., Cutlip, R. C., Richt, J. A., Kehrli, M. E. Jr, Williams, E. S.
(2007). Age-related lesions in laboratory-confined raccoons (Procyon lotor) inoculated with the agent of chronic wasting disease of mule deer. jvdi
19: 680-686
[Abstract][Full Text]
Ritzel, R. A., Meier, J. J., Lin, C.-Y., Veldhuis, J. D., Butler, P. C.
(2007). Human Islet Amyloid Polypeptide Oligomers Disrupt Cell Coupling, Induce Apoptosis, and Impair Insulin Secretion in Isolated Human Islets. Diabetes
56: 65-71
[Abstract][Full Text]
Matveyenko, A. V., Butler, P. C.
(2006). {beta}-Cell Deficit Due to Increased Apoptosis in the Human Islet Amyloid Polypeptide Transgenic (HIP) Rat Recapitulates the Metabolic Defects Present in Type 2 Diabetes.. Diabetes
55: 2106-2114
[Abstract][Full Text]
Stadler, M., Anderwald, C., Karer, T., Tura, A., Kastenbauer, T., Auinger, M., Bieglmayer, C., Wagner, O., Kronenberg, F., Nowotny, P., Pacini, G., Prager, R.
(2006). Increased Plasma Amylin in Type 1 Diabetic Patients After Kidney and Pancreas Transplantation: A sign of impaired {beta}-cell function?. Diabetes Care
29: 1031-1038
[Abstract][Full Text]
Blumenthal, H. T.
(2004). Amyloidosis: A Universal Disease of Aging?. Journals of Gerontology Series A: Biological Sciences and Medical Sciences
59: M361-M369
[Full Text]
Ritzel, R. A., Butler, P. C.
(2003). Replication Increases {beta}-Cell Vulnerability to Human Islet Amyloid Polypeptide-Induced Apoptosis. Diabetes
52: 1701-1708
[Abstract][Full Text]
Kahn, S. E.
(2001). The Importance of {beta}-Cell Failure in the Development and Progression of Type 2 Diabetes. J. Clin. Endocrinol. Metab.
86: 4047-4058
[Full Text]
Xue, B., Zemel, M. B.
(2001). Agouti Signaling Protein Stimulates Islet Amyloid Polypeptide (Amylin) Secretion in Pancreatic {beta}-Cells. Exp. Biol. Med.
226: 565-569
[Abstract][Full Text]
Hoenig, M., Hall, G., Ferguson, D., Jordan, K., Henson, M., Johnson, K., O'Brien, T.
(2000). A Feline Model of Experimentally Induced Islet Amyloidosis. Am. J. Pathol.
157: 2143-2150
[Abstract][Full Text]
Hoppener, J. W.M., Ahren, B., Lips, C. J.M.
(2000). Islet Amyloid and Type 2 Diabetes Mellitus. NEJM
343: 411-419
[Full Text]
Waeber, G., Calandra, T., Roduit, R., Haefliger, J.-A., Bonny, C., Thompson, N., Thorens, B., Temler, E., Meinhardt, A., Bacher, M., Metz, C. N., Nicod, P., Bucala, R.
(1997). Insulin secretion is regulated by the glucose-dependent production of islet beta cell macrophage migration inhibitory factor. Proc. Natl. Acad. Sci. USA
94: 4782-4787
[Abstract][Full Text]
Zunker, P., Schick, A., Buschmann, H.-C., Georgiadis, D., Nabavi, D. G., Edelmann, M., Ringelstein, E. B.
(1996). Hyperinsulinism and Cerebral Microangiopathy. Stroke
27: 219-223
[Abstract][Full Text]
Bennett, R. G., Duckworth, W. C., Hamel, F. G.
(2000). Degradation of Amylin by Insulin-degrading Enzyme. J. Biol. Chem.
275: 36621-36625
[Abstract][Full Text]
Previous
